Position
D. E. Shaw & Co., Inc. in BridgeBio Pharma, Inc.
Back to the book · All holders of BBIO
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$159.3M$76.49 → $4.52
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 2.21M | $169.4M | — | — | — | 0.1% |
| Q1 2026 | 65.3M | $295.6M | $4.52 | −$159.3M | $285.5M | 0.2% |